Capital World Investors’s Adaptimmune Therapeutics ADAP Stock Holding History

Capital World Investors’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-8,002,700	Closed	-$30M	–	579
2021 Q4	$30M	Hold	8,002,700	–	–	﹤0.01%	502
2021 Q3	$41.4M	Hold	8,002,700	–	–	0.01%	474
2021 Q2	$34.1M	Hold	8,002,700	–	–	0.01%	489
2021 Q1	$42.5M	Hold	8,002,700	–	–	0.01%	453
2020 Q4	$43.1M	Hold	8,002,700	–	–	0.01%	427
2020 Q3	$63.9M	Hold	8,002,700	–	–	0.01%	371
2020 Q2	$80.1M	Hold	8,002,700	–	–	0.02%	324
2020 Q1	$21.8M	Buy	8,002,700 +1,210,000	+18%	+$4.02M	0.01%	385
2019 Q4	$8.15M	Hold	6,792,700	–	–	﹤0.01%	469
2019 Q3	$10.3M	Hold	6,792,700	–	–	﹤0.01%	465
2019 Q2	$27.3M	Hold	6,792,700	–	–	0.01%	403
2019 Q1	$29.2M	Hold	6,792,700	–	–	0.01%	393
2018 Q4	$39.1M	Hold	6,792,700	–	–	0.01%	367
2018 Q3	$92.1M	Sell	6,792,700 -394,000	-5%	-$4.13M	0.02%	321
2018 Q2	$85.3M	Buy	7,186,700 +394,000	+6%	+$4.91M	0.02%	315
2018 Q1	$76.3M	Hold	6,792,700	–	–	0.02%	327
2017 Q4	$45.4M	Hold	6,792,700	–	–	0.01%	360
2017 Q3	$55.6M	Hold	6,792,700	–	–	0.01%	349
2017 Q2	$30.5M	Hold	6,792,700	–	–	0.01%	382
2017 Q1	$37.4M	Buy	6,792,700 +2,312,214	+52%	+$10.1M	0.01%	372
2016 Q4	$18.1M	Sell	4,480,486 -120,514	-3%	-$578K	﹤0.01%	408
2016 Q3	$32.4M	Hold	4,601,000	–	–	0.01%	372
2016 Q2	$37.5M	Hold	4,601,000	–	–	0.01%	358
2016 Q1	$37.4M	Hold	4,601,000	–	–	0.01%	358
2015 Q4	$55.5M	Buy	4,601,000 +2,887,082	+168%	+$28.3M	0.02%	336
2015 Q3	$20.5M	Buy	1,713,918 +620,168	+57%	+$8.76M	0.01%	422
2015 Q2	$20M	Buy	+1,093,750	New	+$18.8M	0.01%	442

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital World Investors's ADAP Position: Q1 2022 in Review

Capital World Investors sold out of Adaptimmune Therapeutics (ADAP) in Q1 2022, closing a stake of 8,002,700 shares — an estimated $30M sold.

Capital World Investors first reported a position in ADAP in Q2 2015 and held it in 27 quarters. The position peaked at $92.1M in Q3 2018. 80 funds tracked by Wall St. Rank hold ADAP as of Q1 2022.

Capital World Investors reported no remaining Adaptimmune Therapeutics position as of Q1 2022 after selling out during the quarter.
Capital World Investors sold 8,002,700 Adaptimmune Therapeutics shares in Q1 2022, an estimated $30M.
Capital World Investors first reported a position in Adaptimmune Therapeutics in Q2 2015 and held it in 27 quarters.
Capital World Investors's Adaptimmune Therapeutics position peaked at $92.1M in Q3 2018.
80 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2022.

Based on Capital World Investors's 13F filing for Q1 2022, filed 16 May 2022.